Yair Lotan

59.8k total citations · 14 hit papers
717 papers, 31.4k citations indexed

About

Yair Lotan is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Urology. According to data from OpenAlex, Yair Lotan has authored 717 papers receiving a total of 31.4k indexed citations (citations by other indexed papers that have themselves been cited), including 496 papers in Surgery, 284 papers in Pulmonary and Respiratory Medicine and 139 papers in Urology. Recurrent topics in Yair Lotan's work include Bladder and Urothelial Cancer Treatments (445 papers), Urinary and Genital Oncology Studies (309 papers) and Urological Disorders and Treatments (119 papers). Yair Lotan is often cited by papers focused on Bladder and Urothelial Cancer Treatments (445 papers), Urinary and Genital Oncology Studies (309 papers) and Urological Disorders and Treatments (119 papers). Yair Lotan collaborates with scholars based in United States, Canada and Germany. Yair Lotan's co-authors include Shahrokh F. Shariat, Arthur I. Sagalowsky, Pierre I. Karakiewicz, Claus G. Roehrborn, Jeffrey A. Cadeddu, Margaret S. Pearle, Seth P. Lerner, Vitaly Margulis, Wassim Kassouf and Raheela Ashfaq and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Yair Lotan

680 papers receiving 30.8k citations

Hit Papers

Epidemiology and Risk Fac... 2006 2026 2012 2019 2012 2016 2009 2013 2017 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology and Risk Factors of Urothelial Bladder Cancer
    2012 1.5k citations Pierre I. Karakiewicz, Wassim Kassouf et al. European Urology profile →
  2. Bladder cancer
    2016 1.0k citations Ashish M. Kamat, Per‐Uno Malmström et al. profile →
  3. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
    2009 780 citations Vitaly Margulis, Shahrokh F. Shariat et al. profile →
  4. Systematic Review of Complications of Prostate Biopsy
    2013 735 citations Yair Lotan et al. European Urology profile →
  5. Epidemiology of stone disease across the world
    2017 663 citations Yair Lotan et al. World Journal of Urology profile →
  6. Bladder cancer
    2017 623 citations Yair Lotan et al. profile →
  7. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
    2017 613 citations Ashish M. Kamat, Yair Lotan et al. profile →
  8. Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
    2009 559 citations Yair Lotan et al. European Urology profile →
  9. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
    2018 533 citations Peter C. Black, Ashish M. Kamat et al. European Urology profile →
  10. Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium
    2006 509 citations Shahrokh F. Shariat, Pierre I. Karakiewicz et al. profile →
  11. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
    2015 467 citations Siamak Daneshmand, Yair Lotan et al. European Urology profile →
  12. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease
    2014 393 citations Robert S. Svatek, Yair Lotan et al. European Urology profile →
  13. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
    2016 261 citations Shahrokh F. Shariat, Michael Rink et al. World Journal of Urology profile →
  14. Epidemiology, Screening, and Prevention of Bladder Cancer
    2022 159 citations Marco Moschini, Sima P. Porten et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yair Lotan United States 87 19.7k 11.2k 6.9k 5.8k 5.1k 717 31.4k
Pierre I. Karakiewicz Canada 81 17.0k 0.9× 14.8k 1.3× 3.3k 0.5× 5.9k 1.0× 5.8k 1.1× 1.0k 30.7k
Morgan Rouprêt France 67 17.6k 0.9× 7.4k 0.7× 3.5k 0.5× 6.2k 1.1× 4.2k 0.8× 807 24.5k
James E. Montie United States 70 8.2k 0.4× 10.1k 0.9× 4.7k 0.7× 3.5k 0.6× 3.9k 0.8× 459 20.8k
Stephen A. Boorjian United States 72 9.3k 0.5× 12.2k 1.1× 6.4k 0.9× 2.5k 0.4× 3.9k 0.8× 569 20.8k
Susan Groshen United States 94 11.7k 0.6× 6.2k 0.6× 9.1k 1.3× 2.8k 0.5× 12.0k 2.4× 479 31.8k
Lambertus A. Kiemeney Netherlands 71 7.9k 0.4× 5.2k 0.5× 5.2k 0.8× 3.9k 0.7× 3.8k 0.7× 471 21.5k
John T. Wei United States 73 4.9k 0.2× 13.3k 1.2× 4.7k 0.7× 5.7k 1.0× 3.4k 0.7× 378 23.7k
Shahrokh F. Shariat United States 113 38.1k 1.9× 21.8k 2.0× 9.7k 1.4× 12.4k 2.1× 11.8k 2.3× 1.7k 58.7k
Hendrik Van Poppel Belgium 82 6.5k 0.3× 19.0k 1.7× 6.7k 1.0× 2.3k 0.4× 3.3k 0.6× 567 24.9k
Harry W. Herr United States 86 23.0k 1.2× 5.6k 0.5× 3.5k 0.5× 8.8k 1.5× 4.8k 1.0× 483 27.7k

Countries citing papers authored by Yair Lotan

Since Specialization
Citations

This map shows the geographic impact of Yair Lotan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yair Lotan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yair Lotan more than expected).

Fields of papers citing papers by Yair Lotan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yair Lotan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yair Lotan. The network helps show where Yair Lotan may publish in the future.

Co-authorship network of co-authors of Yair Lotan

This figure shows the co-authorship network connecting the top 25 collaborators of Yair Lotan. A scholar is included among the top collaborators of Yair Lotan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yair Lotan. Yair Lotan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jong, Joep J. de, Siamak Daneshmand, Robert S. Svatek, et al.. (2025). Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy. European Urology Open Science. 73. 24–30. 1 indexed citations
2.
Woldu, Solomon L., Daniel Halstuch, Yaara Ber, et al.. (2025). Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure. Urologic Oncology Seminars and Original Investigations. 43(6). 391.e1–391.e10. 1 indexed citations
3.
Daneshmand, Siamak, Renata Zaucha, Nikhil Vasdev, et al.. (2024). MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS. Urologic Oncology Seminars and Original Investigations. 42. S58–S58. 1 indexed citations
4.
Rose, Kyle, Katie S. Murray, Solomon L. Woldu, et al.. (2023). Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. European Urology Focus. 9(5). 807–812. 7 indexed citations
5.
Gold, Samuel, Ramy Goueli, Ryan Mauck, et al.. (2023). Optimal Prostate Cancer Diagnostic Pathways for Men With Prostatomegaly in the MRI Era. Urology. 179. 95–100.
6.
Bhanvadia, Raj, Yair Lotan, Vitaly Margulis, et al.. (2022). Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. Journal of Endourology. 36(8). 1070–1076. 4 indexed citations
7.
Schuettfort, Victor M., Benjamin Pradère, Quoc‐Dien Trinh, et al.. (2021). Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology Immunotherapy. 71(1). 85–95. 13 indexed citations
8.
Chu, Carissa, Martin Sjöström, Emily A. Egusa, et al.. (2021). Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clinical Cancer Research. 27(18). 5123–5130. 101 indexed citations
9.
Ghandour, Rashed, Daniel Wong, Xiaosong Meng, et al.. (2020). Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. Urologic Oncology Seminars and Original Investigations. 38(9). 736.e11–736.e18. 12 indexed citations
10.
Lotan, Yair, Trinity J. Bivalacqua, Tracy M. Downs, et al.. (2019). Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018. Nature Reviews Urology. 16(6). 377–386. 59 indexed citations
11.
Smith, Angela B., Siamak Daneshmand, Sanjay Patel, et al.. (2018). Patient‐reported outcomes of blue‐light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. British Journal of Urology. 123(1). 35–41. 9 indexed citations
12.
Passoni, Niccolò, Bishoy A. Gayed, Payal Kapur, et al.. (2016). Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non–muscle-invasive high-grade bladder cancer. Urologic Oncology Seminars and Original Investigations. 34(11). 485.e7–485.e14. 19 indexed citations
13.
Feng, Ziding, Roman Gulati, Jing Fan, et al.. (2015). Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention. 24(4). 677–682. 15 indexed citations
14.
Palmbos, Phillip L., Lidong Wang, Huibin Yang, et al.. (2015). ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms. Cancer Research. 75(23). 5155–5166. 60 indexed citations
15.
Krabbe, Laura-Maria, Aditya Bagrodia, Mary E. Westerman, et al.. (2015). Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. World Journal of Urology. 34(1). 105–112. 6 indexed citations
16.
Chung, Woonbok, Jolanta Bondaruk, Jaroslav Jelı́nek, et al.. (2011). Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine Sediments. Cancer Epidemiology Biomarkers & Prevention. 20(7). 1483–1491. 127 indexed citations
17.
Brikowski, Tom, Yair Lotan, & Margaret S. Pearle. (2008). Climate-related increase in the prevalence of urolithiasis in the United States. Proceedings of the National Academy of Sciences. 105(28). 9841–9846. 270 indexed citations
18.
Kikuchi, Eiji, Vitaly Margulis, Pierre I. Karakiewicz, et al.. (2008). Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology. 27(4). 612–618. 215 indexed citations
19.
Margulis, Vitaly, Yair Lotan, & Shahrokh F. Shariat. (2007). Survivin: a promising biomarker for detection and prognosis of bladder cancer. World Journal of Urology. 26(1). 59–65. 77 indexed citations
20.
Walsh, Lance P., Jennifer Stanfield, Kenneth Forster, et al.. (2006). Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model. European Urology. 50(4). 795–800. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre I. Karakiewicz Breakdown of academic impact, for papers by Morgan Rouprêt Breakdown of academic impact, for papers by James E. Montie Breakdown of academic impact, for papers by Stephen A. Boorjian Breakdown of academic impact, for papers by Susan Groshen Breakdown of academic impact, for papers by Lambertus A. Kiemeney Breakdown of academic impact, for papers by John T. Wei Breakdown of academic impact, for papers by Shahrokh F. Shariat Breakdown of academic impact, for papers by Hendrik Van Poppel Breakdown of academic impact, for papers by Harry W. Herr
Rankless by CCL
2026